Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

iwMPN 2026 | Approaching the selection between rusfertide and interferons when treating PV: advice for clinicians

Abdulraheem Yacoub, MD, University of Kansas Medical Center, Kansas City, KS, discusses the role of rusfertide in the treatment of polycythemia vera (PV) and how clinicians should approach the selection between rusfertide and interferons. Dr Yacoub notes that rusfertide will not replace standard treatments for high-risk patients, but can be used with interferon or as an alternative for low-risk patients managed with phlebotomy alone. This interview took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, D.C.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Yeah, we’re very excited that we have one more option for treating our patients with PV. Rusfertide is a great scientific advancement in which we utilize the ability of modulating a hepcidin pathway to avoid phlebotomy. This is a very specific therapy that is very capable of delivering the success as we define on those studies, which is eliminating phlebotomy. So rusfertide is not a cytoreductive therapy...

Yeah, we’re very excited that we have one more option for treating our patients with PV. Rusfertide is a great scientific advancement in which we utilize the ability of modulating a hepcidin pathway to avoid phlebotomy. This is a very specific therapy that is very capable of delivering the success as we define on those studies, which is eliminating phlebotomy. So rusfertide is not a cytoreductive therapy. rusfertide is not going to replace our standard platform of how we treat patients with PV, especially the high-risk patients. So for high-risk patients, cytoreductive therapy with interferon or as a preferred agent or others, like hydroxyurea, remains the platform of how we treat patients. Rusfertide would be useful in these patients who are still in cytoreductive therapy and still require phlebotomy. So a combination of interferon and rusfertide is very plausible, actually, in many patients in the future. Now, the question comes to patients who are lower risk, in which cytoreductive therapy is not yet absolutely necessary or indicated, and those patients are being managed by phlebotomy only, those patients are absolutely on label for rusfertide therapy. On the same token, and this is a topic of interest for me personally with an upcoming clinical trial, is that interferons also have shown a very promising activity in patients with low-risk PV in terms of disease modification, clinical responses, and molecular responses. Now, this was studied in a limited prospective European study, but we are in the process of designing a global interventional clinical trial for low-risk PV patients that will be randomized, in which patients who are low-risk PV patients will be randomized to early intervention with interferon. Now, when that work is complete, that will inform our future care for patients with low-risk PV and define the role of interferons in low-risk PV. That being said, rusfertide remains a very important tool for hematocritic control and avoidance of phlebotomy in parallel to whatever else we’re doing, both in high-risk PV patients and in low-risk PV patients. And it’s definitely a tool that’s here to stay. We already have second and third generation agents in the works, so obviously there’s a significant buy-in from the community that this is an important tool for our future patients.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.